Charles McWherter - Nov 17, 2023 Form 4 Insider Report for CymaBay Therapeutics, Inc. (CBAY)

Role
President of R&D
Signature
/s/ Paul Quinlan, as attorney-in-fact for Charles McWherter
Stock symbol
CBAY
Transactions as of
Nov 17, 2023
Transactions value $
-$150,583
Form type
4
Date filed
11/17/2023, 05:58 PM
Previous filing
Oct 18, 2023
Next filing
Dec 18, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CBAY Common Stock Options Exercise $56.7K +11.3K +75.61% $5.00 26.3K Nov 17, 2023 Direct
transaction CBAY Common Stock Sale -$207K -11.3K -43.06% $18.28 15K Nov 17, 2023 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CBAY Employee Stock Option (right to buy) Options Exercise $0 -708 -50.14% $0.00 704 Nov 17, 2023 Common Stock 708 $5.00 Direct F3
transaction CBAY Employee Stock Option (right to buy) Options Exercise $0 -236 -50.21% $0.00 234 Nov 17, 2023 Common Stock 236 $5.00 Direct F4
transaction CBAY Employee Stock Option (right to buy) Options Exercise $0 -3.89K -50.01% $0.00 3.89K Nov 17, 2023 Common Stock 3.89K $5.00 Direct F5
transaction CBAY Employee Stock Option (right to buy) Options Exercise $0 -6.51K -50.01% $0.00 6.5K Nov 17, 2023 Common Stock 6.51K $5.00 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into on February 24, 2023.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.188 to $18.43, inclusive. The reporting person undertakes to provide to CymaBay Therapeutics, Inc., any security holder of CymaBay Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The original option vested as to 1/4 of the underlying shares on July 23, 2008 and the remaining 3/4 of the underlying shares vested ratably on a monthly basis over the 36 months thereafter.
F4 The original option vested as to 1/48 of the underlying shares monthly from October 15, 2009.
F5 The option vested in full on December 23, 2015.
F6 The option vested as to 1/3 of the underlying shares on January 6, 2014 and the remaining 2/3 of the underlying shares vested ratably on a monthly basis over the 48 months thereafter.